Table 3.
Treatments in the study analysis population as a function of treating physician
| GPs N = 810 |
Rheumatologists N = 317 |
Gynaecologists N = 179 |
p | Total N = 1306 |
|
|---|---|---|---|---|---|
| ON GOING TREATMENT | 526 (64.9%) | 150 (47.3%) | 70 (39.1%) | ≤ 0.001 | 746 (57.1%) |
| Bisphosphonates | 412 (78.3%) | 98 (65.3%) | 33 (47.1%) | ≤ 0.001 | 543 (72.8%) |
| Daily | 14 (3.5%) | 2 (2.1%) | 1 (3.2%) | NS | 17 (3.2%) |
| Weekly | 227 (56.9%) | 60 (63.8%) | 18 (58.1%) | 305 (58.2%) | |
| Monthly | 158 (39.6%) | 32 (34.0%) | 12 (38.7%) | 202 (38.6%) | |
| SERM | 47 (8.9%) | 14 (9.3%) | 15 (21.4%) | 0.009 | 76 (10.2%) |
| Strontium ranelate | 68 (12.9%) | 34 (22.7%) | 17 (24.3%) | 0.003 | 119 (16.0%) |
| Other | 10 (1.9%) | 4 (2.7%) | 12 (17.1%) | ≤ 0.001 | 26 (3.5%) |
| SUPPLEMENTATION | 671 (82.8%) | 269 (84.9%) | 146 (81.6%) | NS | 1086 (83.2%) |
| Supplementation Type | N = 655 | N = 268 | N = 141 | N = 1064 | |
| Calcium | 33 (5.0%) | 7 (2.6%) | 3 (2.1%) | 0.073 | 43 (4.0%) |
| Vitamin D | 27 (4.1%) | 20 (7.5%) | 9 (6.4%) | 56 (5.3%) | |
| Calcium + Vitamin D | 595 (90.8%) | 241 (89.9%) | 129 (91.5%) | 965 (90.7%) |
For the individual osteoporosis treatments, only treatments ongoing at the time of the consultation are considered. Percentages for individual treatments are calculated with respect to the total number of patients with an ongoing treatment. Percentages for bisphosphonate treatment regimens are calculated with respect to the total number of patients taking a bisphosphonate. Percentages for supplementation type are calculated with respect to the total number of patients taking supplementation. SERM: selective oestrogen receptor modulators. NS: not significant. Between group differences were determined with the Kruskal-Wallis test.